BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9316174)

  • 1. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy.
    Morinobu S; Tanaka T; Kawakatsu S; Totsuka S; Koyama E; Chiba K; Ishizaki T; Kubota T
    Psychiatry Clin Neurosci; 1997 Aug; 51(4):253-7. PubMed ID: 9316174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4.
    Madsen H; Rasmussen BB; Brøsen K
    Clin Pharmacol Ther; 1997 Mar; 61(3):319-24. PubMed ID: 9084457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
    Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
    Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.
    Schenk PW; van Vliet M; Mathot RA; van Gelder T; Vulto AG; van Fessem MA; Verploegh-Van Rij S; Lindemans J; Bruijn JA; van Schaik RH
    Pharmacogenomics J; 2010 Jun; 10(3):219-25. PubMed ID: 19884907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
    Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
    Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
    Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
    de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
    Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
    Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
    Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
    Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
    Kubota T; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
    Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
    Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
    Zhou HH
    Clin Chim Acta; 2001 Nov; 313(1-2):203-8. PubMed ID: 11694260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.